The global health and economic value of Covid-19 vaccination
Bibliographic Data
| ID | 21879036 |
|---|---|
| Authors | J P Sevilla (0000-0001-9807-657X, Harvard University), JP Sevilla (Data for Decisions, LLC, Waltham, Massachusetts, USA), Daria Burnes (0000-0002-8624-1344, Health Decisions (United States)), Joseph S Knee (0000-0001-5300-4206, Health Decisions (United States)), Manuela Di Fusco (0000-0003-0079-7331, Pfizer (United States)), Moe H Kyaw (0000-0002-0258-6645, Pfizer (United States)), Jingyan Yang (0000-0001-5523-649X, Pfizer (United States)), Jennifer L Nguyen (0000-0002-4064-0227, Pfizer (United States)), David E Bloom (0000-0003-3731-3345, Harvard University) |
| Year | 2024 |
| Volume | 9 |
| Issue | 9 |
| Pages | e015031 |
| Publication date | 2024-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2024-015031 |
| PMID | 39244220 |
| OpenAlex | W4402333790 |
| Language | EN |
| Citations received | 2 |
| References cited | 22 |
INTRODUCTION: The COVID-19 pandemic triggered one of the largest global health and economic crises in recent history. COVID-19 vaccination (CV) has been the central tool for global health and macroeconomic recovery, yet estimates of CV's global health and macroeconomic value remain scarce. METHODS: We used regression analyses to measure the impact of CV on gross domestic product (GDP), infections and deaths. We combined regression estimates of vaccine-averted infections and deaths with estimates of quality-adjusted life years (QALY) losses, and direct and indirect costs, to estimate three broad value components: (i) QALY gains, (ii) direct and indirect costs averted and (iii) GDP impacts. The global value is the sum of components over 148 countries between January 2020 and December 2021 for CV generally and for Pfizer-BioNTech specifically. RESULTS: CV's global value was US$5.2 (95% CI US$4.1 to US$6.2) trillion, with Pfizer-BioNTech's vaccines contributing over US$1.9 (95% CI US$1.5 to US$2.3) trillion. Varying key parameters results in values 10%-20% higher or lower than the base-case value. The largest value component was GDP impacts, followed by QALY gains, then direct and indirect costs averted. CV provided US$740 of value per dose, while Pfizer-BioNTech specifically provided >US$1600 per dose. We estimated conservative benefit-cost ratios of 13.9 and 30.8 for CV and Pfizer-BioNTech, respectively. CONCLUSIONS: We provide the first estimates of the broad value of CV incorporating GDP, QALY and direct and indirect cost impacts. Through December 2021, CV produced significant health and economic value, represented strong value for money and produced significant macroeconomic benefits that should be considered in vaccine evaluation
2019-20 coronavirus outbreak · Global health · Outbreak · Pandemic · Public health · Statistics · Vaccination · COVID-19 Pandemic Impacts · Mathematics · Medicine · Nursing · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Virology
Self-Reported Population Health
Global impact of the first year of Covid-19 vaccination
Biases in Dynamic Models with Fixed Effects
Some Tests of Specification for Panel Data
Initial conditions and moment restrictions in dynamic panel data models
Valuing Covid-19 Morbidity Risk Reductions
The Value of Health and Longevity
| Unique citing works | 2 |
|---|---|
| Citations per year | 2 |
| Citation span | 2026 - 2026 (1) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 2 |